Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea — ERASE

Traveler's Diarrhea Clinical Trial

Official title:
A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers

Status Completed

Clinical Trial Summary

The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01208922
Study type	Interventional
Source	Dr. Falk Pharma GmbH
Contact
Status	Completed
Phase	Phase 3
Start date	November 2010
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00672035` - Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study	Phase 2
Completed	`NCT01142089` - Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)	Phase 3
Not yet recruiting	`NCT04026984` - Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Phase 2
Not yet recruiting	`NCT04027894` - Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Phase 2
Completed	`NCT03866291` - ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
Completed	`NCT03301103` - PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli	N/A
Completed	`NCT01040325` - Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study	Phase 2
Withdrawn	`NCT02736539` - Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea	Phase 3